Combined Dupilumab and House Dust Mite Sublingual Immunotherapy Provides Sustained Clinical and Immunologic Benefits in Severe Atopic Dermatitis: 3-Year Results of a Randomized Controlled Study.
文献摘要
Background Atopic dermatitis (AD) is a chronic inflammatory skin disease frequently associated with house dust mite (HDM) sensitization. Although dupilumab effectively suppresses type 2 inflammation, it does not induce allergen-specific immune tolerance. Objective To evaluate long-term clinical and immunologic outcomes of combined dupilumab and HDM sublingual immunotherapy (HDM-SLIT) compared with monotherapies in severe AD. Methods In this prospective, randomized, open-label, three-center study, 65 adults with severe AD and HDM sensitization were assigned to HDM-SLIT (n=15), dupilumab (n=15), combination therapy (n=20), or cyclosporine (n=15). Cyclosporine was administered for 12 months only. Clinical outcomes and immunologic biomarkers were assessed at baseline and at 12, 24, and 36 months. Longitudinal treatment-by-time effects were evaluated with repeated-measures analysis, with adjusted post-hoc pairwise comparisons. Clinicaltrials gov identifier: NCT06509243. Results All groups improved at 12 months. Repeated-measures ANOVA demonstrated a significant treatment-by-time interaction for EASI (F(9,183) = 42.16, P Conclusions Combined dupilumab and HDM-SLIT was associated with sustained clinical improvement and broader immunologic modulation than either therapy alone. These findings support further evaluation of this strategy as a potential disease-modifying approach in severe HDM-sensitized AD; confirmation in larger trials and after treatment withdrawal is required.